Condition: Medulloblastoma · Sponsor: Giselle Sholler
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
This description comes directly from the study's public registry record.
BCC Enroll · 7175310003 · BCCEnroll@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| Connecticut Children's Hospital | Hartford, Connecticut, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| Arnold Palmer Hospital for Children | Orlando, Florida, United States | Recruiting |
| All Children's Hospital Johns Hopkins Medicine | St. Petersburg, Florida, United States | Recruiting |
| St. Joseph's Children's Hospital | Tampa, Florida, United States | Recruiting |
| Kapiolani Medical Center for Women and Children | Honolulu, Hawaii, United States | Recruiting |
| Advocate Aurora Research Institute | Chicago, Illinois, United States | Recruiting |
| Kentucky Children's Hospital | Lexington, Kentucky, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04696029